<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00358163</url>
  </required_header>
  <id_info>
    <org_study_id>05-046</org_study_id>
    <nct_id>NCT00358163</nct_id>
  </id_info>
  <brief_title>Trial of PTK787/ZK 222584 Plus Paclitaxel</brief_title>
  <official_title>Phase I Study of the Oral Vascular Endothelial Growth Factor Inhibitor PTK787/ZK 222584 in Combination With Paclitaxel in Patients With Advanced Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      PTK787/ZK 222584 is an inhibitor of VEGFR family tyrosine kinases. The primary objective of&#xD;
      this study is to assess the safety of daily oral PTK787/ZK 222584 in combination with&#xD;
      paclitaxel infused every 21 days. Secondary objectives include pharmacokinetic assessment of&#xD;
      the impact of PTK787/ZK 222584 on paclitaxel metabolism and evaluation of tumor response to&#xD;
      the investigational treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  We are looking for the highest dose of Paclitaxel that can be given safely in&#xD;
           combination with the highest safe dose of Vatalanib. Therefore, not all people will&#xD;
           receive the same dose of the study drug.&#xD;
&#xD;
        -  Small groups of people will be enrolled in steps on this trial. This first group will be&#xD;
           given a certain dose of Paclitaxel and Vatalanib. If they have few or manageable side&#xD;
           effects, the next small group of people enrolled will receive higher doses of the study&#xD;
           drugs. This increase in doses will continue until the study doctors find the highest&#xD;
           dose of the drugs that can be given without causing severe or unmanageable side effects.&#xD;
&#xD;
        -  In this study, Vatalanib tablets are taken daily, and paclitaxel is given by three-hour&#xD;
           intravenous infusion once every 21 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">April 2010</completion_date>
  <primary_completion_date type="Anticipated">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of PTK787/ZK 222584 in combination with paclitaxel</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic effect of PTK787/ZK 222584 on paclitaxel metabolism. Clinical tumor response to study treatment.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Metastatic Non-hematologic Malignancies</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTK787/ZK 222584</intervention_name>
    <description>Taken in tablet form daily</description>
    <other_name>Vatalanib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given as a 3-hour infusion once every 21 days</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with advanced solid tumors for whom there is no potentially curative&#xD;
             treatment (surgery, radiation therapy or chemotherapy).&#xD;
&#xD;
          -  Measurable or non-measurable disease&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  ECOG Performance Status 0 -1&#xD;
&#xD;
          -  Laboratory values ≤ 14 days weeks prior to starting study treatment:&#xD;
&#xD;
          -  Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L (≥ 1500/mm3)&#xD;
&#xD;
          -  Platelets (PLT) ≥ 100 x 109/L (≥ 100,000/mm3)&#xD;
&#xD;
          -  Hemoglobin (Hgb) ≥ 9 g/dL&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 ULN&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.0 x ULN&#xD;
&#xD;
          -  Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 2.5 x&#xD;
             ULN (≤ CTC grade 1).&#xD;
&#xD;
          -  Negative for proteinuria based on dip stick reading OR, if documentation of +1 result&#xD;
             for protein on dip stick reading, then total urinary protein ≤ 500 mg and measured&#xD;
             creatinine clearance (CrCl) ≥ 50 mL/min from a 24-hour urine collection&#xD;
&#xD;
          -  Women of child-bearing age must have a negative serum or urine test.&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Written informed consent obtained&#xD;
&#xD;
          -  Resolution of toxicity from previous chemotherapy to ≤ Grade I.&#xD;
&#xD;
          -  QTc interval ≤ 0.45 seconds (men) or ≤ 0.47 seconds (women).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous hypersensitivity reaction to taxanes or cremophor.&#xD;
&#xD;
          -  History or presence of central nervous system (CNS) disease (i.e., primary brain&#xD;
             tumor, malignant seizures, CNS metastases or carcinomatous meningitis).&#xD;
&#xD;
          -  Prior chemotherapy ≤ 4 weeks prior to registration. Prior nitrosoureas or mitomycin C&#xD;
             ≤ 6 weeks prior to registration.&#xD;
&#xD;
          -  Prior biologic or immunotherapy ≤ 2 weeks prior to registration. Patients must have&#xD;
             recovered from all therapy-related toxicities&#xD;
&#xD;
          -  Prior radiotherapy ≤ 4 weeks prior to registration. Patients must have recovered from&#xD;
             all therapy-related toxicities. The site of previous radiotherapy should have evidence&#xD;
             of progressive disease if this is the only site of disease&#xD;
&#xD;
          -  Major surgery (i.e., laparotomy) ≤ 4 weeks prior to registration. Minor surgery ≤ 2&#xD;
             weeks prior to registration. Insertion of a vascular access device is not considered&#xD;
             major or minor surgery in this regard. Patients must have recovered from all&#xD;
             surgery-related toxicities&#xD;
&#xD;
          -  Patients who have received investigational drugs ≤ 4 weeks prior to registration.&#xD;
&#xD;
          -  Peripheral neuropathy with functional impairment ≥ CTC grade 2 neuropathy, regardless&#xD;
             of causality.&#xD;
&#xD;
          -  Pleural effusion or ascites that causes respiratory compromise (≥ CTC grade 2 dyspnea)&#xD;
&#xD;
          -  Female patients who are pregnant or breast-feeding, or adults of reproductive&#xD;
             potential who are not employing an effective method of birth control. Barrier&#xD;
             contraceptives must be used throughout the trial in both sexes. Oral, implantable, or&#xD;
             injectable contraceptives may be affected by cytochrome P450 interactions, and are&#xD;
             therefore not considered effective for this study. Please refer to appendix for a list&#xD;
             of examples of substrates of human liver microsomal P450 enzymes&#xD;
&#xD;
          -  Any of the following concurrent severe and/or uncontrolled medical conditions which&#xD;
             could compromise participation in the study:&#xD;
&#xD;
          -  Uncontrolled high blood pressure, history of labile hypertension, or history of poor&#xD;
             compliance with an antihypertensive regimen&#xD;
&#xD;
          -  Unstable angina pectoris&#xD;
&#xD;
          -  Symptomatic congestive heart failure&#xD;
&#xD;
          -  Myocardial infarction ≤ 6 months prior to registration and/or randomization&#xD;
&#xD;
          -  Serious uncontrolled cardiac arrhythmia&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  Active or uncontrolled infection&#xD;
&#xD;
          -  Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung&#xD;
&#xD;
          -  Acute or chronic liver disease (eg., hepatitis, cirrhosis)&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of PTK787/ZK 222584 (i.e., ulcerative disease, uncontrolled&#xD;
             nausea, vomiting, diarrhea, malabsorption syndrome, bowel obstruction, or inability to&#xD;
             swallow the tablets)&#xD;
&#xD;
          -  Patients with confirmed diagnosis of human immunodeficiency virus (HIV) infection are&#xD;
             excluded at the investigator's discretion if he/she feels that 1) a potential drug&#xD;
             interaction between PTK787/ZK 222584, paclitaxel and any of the patient's anti-HIV&#xD;
             medications could influence the efficacy of the anti-HIV medication, or 2) it may&#xD;
             place the patient at risk due to the pharmacologic activity of PTK787/ZK 222584.&#xD;
             Please refer to appendix for a list of examples of substrates of human liver&#xD;
             microsomal P450 enzymes&#xD;
&#xD;
          -  Patients who are taking therapeutic warfarin sodium (Coumadin) or similar oral&#xD;
             anticoagulants that are metabolized by the cytochrome P450 system. Heparin products&#xD;
             are allowed. Please refer to appendix for a list of examples of substrates of human&#xD;
             liver microsomal P450 enzymes&#xD;
&#xD;
          -  Patients unwilling to or unable to comply with the protocol&#xD;
&#xD;
          -  Use of recombinant G-CSF products (Neupogen, Neulasta) within three weeks of&#xD;
             registration. Chronic use of recombinant erythropoietin is permitted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pankaj Bhargava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>July 28, 2006</study_first_submitted>
  <study_first_submitted_qc>July 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2006</study_first_posted>
  <last_update_submitted>October 30, 2009</last_update_submitted>
  <last_update_submitted_qc>October 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Eunice Kwak, MD</name_title>
    <organization>Massachusetts General Hospital</organization>
  </responsible_party>
  <keyword>angiogenesis</keyword>
  <keyword>taxane</keyword>
  <keyword>tyrosine kinase</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Vatalanib</keyword>
  <keyword>Taxol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vatalanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

